Device Trial Radar · NCT07571733
Study on the Efficacy of Spinal Cord Stimulation in Patients With Severe Refractory Primary or Secondary RLS
Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Feb 14, 2029
Study completion Feb 14, 2029
Sponsor
- Lead sponsor
- Clinica ARS MedicaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 6, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Double-Blind Randomized Controlled Crossover Study to compare the short-efficacy of Burst-SCS with Sham Stimulation, in patients with severe to very severe RLS refractory or intolerant to standard available treatments and/or patients in augmentation, with a two-period-alternating treatment design.
Conditions
- Restless Leg Syndrome (RLS)
Interventions
Spinal cord stimulation (SCS)Device
Burst SCS, a specific spinal cord stimulation waveform that delivers pulses in clusters separated by brief periods without stimulation, is chosen over other modalities due to its demonstrated ability to modulate both the sensory and affective components of pain and discomfort. Unlike traditional tonic stimulation, Burst SCS delivers stimulation patterns that more closely resemble natural neuronal firing, and may provide effective symptom relief without inducing paresthesia.
Sham stimulationDevice
For the Sham stimulation condition, the amplitude of the spinal cord stimulation will be set to zero.
Primary outcomes
What the sponsor says the trial is designed to measure.
- RLS symptom severityTime frame: From baseline of the treatment phase to the end of the 2.5 months treatment phase
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Clinica Ars Medica
Gravesano, Canton Ticino, Switzerland
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.